Biologics and Small Molecules in Ulcerative Colitis and Crohn's Disease: Current Evidence and Clinical Relevance
The treatment of the chronic inflammatory bowel diseases (IBD) ulcerative colitis and Crohn’s disease has made significant progress with the introduction of biologics and small molecules. In addition to conventional immunosuppressants, targeted modulators of inflammatory pathways – such as TNF-α inh...
Saved in:
| Main Author: | Stephan Vavricka |
|---|---|
| Format: | Article |
| Language: | deu |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2025-06-01
|
| Series: | healthbook TIMES Das Schweizer Ärztejournal Journal Des Médecins Suisses |
| Online Access: | https://doi.org/10.36000/hbT.2025.17.004 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Small Molecules in the Treatment of Acute Severe Ulcerative Colitis: A Review of Current Evidence
by: Raffaele Pellegrino, et al.
Published: (2025-02-01) -
Mucosal Barrier in Ulcerative Colitis and Crohn’s Disease
by: A. E. Dorofeyev, et al.
Published: (2013-01-01) -
BIOLOGICAL THERAPY IN ADULT PATIENTS WITH ULCERATIVE COLITIS AND CROHN’S DISEASE: BUDGET IMPACT ANALYSIS
by: E. A. Pyadushkina
Published: (2017-05-01) -
CLINICOPATHOLOGIC PECULIARITIES OF NONSPECIFIC ULCERATIVE COLITIS AND CROHN'S DISEASE
by: S. D. Strelkova, et al.
Published: (2021-07-01) -
Two for One: Coexisting Ulcerative Colitis and Crohn’s Disease
by: Grant I Chen, et al.
Published: (2002-01-01)